INOVIO Pharmaceuticals announced a public offering of approximately 58.7 million shares and pre-funded warrants to raise about $75 million before expenses. The offering price is set at $1.05 per share, with an option for underwriters to buy additional shares. Proceeds will support INOVIO's work on DNA medicines targeting HPV-related diseases, cancer, and infectious diseases. The offering is expected to close around November 9, 2026, pending customary conditions.
INOVIO Pharmaceuticals shares trade at USD 1.25 on Pluang as of Nov 06, 2026 11:01 WIB, down 22.84% in one day. The stock's market cap stands at $166.99 million with a volume of 21,106,658 shares. Pluang order activity shows a slight selling bias at 54% Sell versus 46% Buy.
INOVIO, a biotech company specializing in DNA medicines for HPV-related diseases and cancer, will announce its Q3 2026 financial results after market close on November 10, 2026. The company will hold a live conference call and webcast at 4:30 p.m. ET...
INOVIO, a biotech company specializing in DNA medicines for HPV-related diseases, cancer, and infectious diseases, announced it will present at two upcoming scientific conferences in November 2026. The presentations will cover next-generation DNA med...
